RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
Reclassification of a Variant of Thyroid Carcinoma https://t.co/o1ZsqjYu7n https://t.co/288ystK6lB
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
RT @chioseasi: Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48L…
Digital slides of #NIFTP are here: https://t.co/OHmqtMfCxC? #PathJC 8/23 9PM EST https://t.co/k8Rfm6QMjq https://t.co/Slb48LpB7d
RT @path_JC: T-2 weeks to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.…
RT @path_JC: T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.c…
RT @JAMAOnc: Reclassification of a Variant of Thyroid Carcinoma https://t.co/xwngvLydZP
RT @JAMAOnc: Reclassification of a Variant of Thyroid Carcinoma https://t.co/xwngvLydZP
RT @JAMAOnc: Reclassification of a Variant of Thyroid Carcinoma https://t.co/xwngvLydZP
RT @JAMAOnc: Reclassification of a Variant of Thyroid Carcinoma https://t.co/xwngvLydZP
RT @JAMAOnc: Reclassification of a Variant of Thyroid Carcinoma https://t.co/xwngvLydZP
RT @JAMAOnc: Reclassification of a Variant of Thyroid Carcinoma https://t.co/xwngvLydZP
Reclassification of a Variant of Thyroid Carcinoma https://t.co/xwngvLydZP
RT @path_JC: T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.c…
Reclassification of a Variant of Thyroid Carcinoma https://t.co/5K5eE2nBIJ https://t.co/TtcJV3ILIg
RT @path_JC: T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.c…
RT @path_JC: T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.c…
RT @path_JC: T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.c…
RT @path_JC: T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.c…
RT @path_JC: T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.c…
RT @path_JC: T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.c…
T-1 week to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.co/o2XojE8Uea
RT @chioseasi: #NIFTP paper - OPEN access https://t.co/b05TECas7H #PathJC 8/23 9PM EST! Details https://t.co/eH3wxGwRO8 https://t.co/oVzyXe…
RT @path_JC: T-2 weeks to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.…
RT @path_JC: T-2 weeks to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.…
RT @path_JC: T-2 weeks to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.…
RT @path_JC: T-2 weeks to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.…
T-2 weeks to next #PathJC 8/23 9PM EST! https://t.co/OE8nP9mArC Topic: NIFTP Paper @JAMAOnc https://t.co/e5kpnwJwMP https://t.co/Nv09JzwD2A
RT @DiplomadoCito: Reclassification of a Variant of Thyroid Carcinoma https://t.co/sPXobZ5SDx
Reclassification of a Variant of Thyroid Carcinoma https://t.co/sPXobZ5SDx
Reclassification of a Variant of Thyroid Carcinoma https://t.co/FTQZWU1gkL. #Pathology
Reclassification of a Variant of Thyroid Carcinoma https://t.co/ruBQoWf1N7
Reclassification of a Variant of Thyroid Carcinoma https://t.co/zJclTbUkd2
RT @kazparis: ちなみに先ほどの非転移型濾胞型甲状腺乳頭癌の記事に関して、ルモンド紙が根拠にしていた資料は、JAMA Ontologyの以下の論文(英語)https://t.co/5jh2LJzQc6
RT @UCD_Cancer: News flash on April 2016: Researchers suggest EFVPTC maybe not a “cancer.” https://t.co/cvpSymHEPi #CancerOrNot
News flash on April 2016: Researchers suggest EFVPTC maybe not a “cancer.” https://t.co/cvpSymHEPi #CancerOrNot
RT @Links_Medicus: Reclassification of a Variant of Thyroid Carcinoma https://t.co/mw47ogZCLa
ちなみに先ほどの非転移型濾胞型甲状腺乳頭癌の記事に関して、ルモンド紙が根拠にしていた資料は、JAMA Ontologyの以下の論文(英語)https://t.co/5jh2LJzQc6
When Cancer Isn’t Cancer? Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma https://t.co/5YC5GjNTLd
RT @NIFTP: See latest on the New Thyroid Tumour; NIFTP https://t.co/0TNQVCtbqw An important step with major implications for patients
Reclassification of a Variant of Thyroid Carcinoma https://t.co/zoupXMdUPD
RT @IlindelatorreMD: Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. https://t.co/tuS0aFJKlY
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. https://t.co/tuS0aFJKlY
The search for more accurate diagnosis #thyroid cancer An expert panel weighs in on PTC #thyroid carcinoma https://t.co/QySq31IGxs @JAMAOnc
RT @PriamalFear: @PriamalFear - A Paradigm Shift to Reduce Overtreatment of Indolent Tumors https://t.co/uutbvj2NRE
@PriamalFear - A Paradigm Shift to Reduce Overtreatment of Indolent Tumors https://t.co/uutbvj2NRE
RT @SBP_Nacional: Estudo divulgado pela @JAMAOnc,diz que 20% dos tumores da tireoide podem ser reclassificados:https://t.co/F2GXZ3azqH http…
RT @SBP_Nacional: Estudo divulgado pela @JAMAOnc,diz que 20% dos tumores da tireoide podem ser reclassificados:https://t.co/F2GXZ3azqH http…
New study finds that many cases of #Thyroid tumors are misdiagnosed & treated as #ThyroidCancer: https://t.co/3g1siD9L52 #cancer #HealthNews
One way to change this is renaming more indolent tumors, as recently seen in Nikiforov et al https://t.co/hrUvC755Un https://t.co/tDdPUR6RUR
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma https://t.co/NZ64b3e7ql
Reclassification of a Variant of Thyroid Carcinoma https://t.co/4Ksg6SdIPn
Nomenclature Revision for Papillary Thyroid Ca: Paradigm Shift to Reduce OverRx of Indolent Tumors https://t.co/f8Xk3b9ivT via @JAMAOnc
RT @Tom_J_Giordano: My first #NIFTP thyroid tumor - consult case from Lansing. https://t.co/wDyqRxjRTv https://t.co/8p65qLVJ1u https://t.co…
Estudo divulgado pela @JAMAOnc,diz que 20% dos tumores da tireoide podem ser reclassificados:https://t.co/F2GXZ3azqH https://t.co/0iAS0h4Vua
Congrats! CHTN's Dr. Virginia LiVolsi is a co-author on the newly designated Thyroid Tumor NIFT-P in JAMA Oncology! https://t.co/hMclRYwvzx
RT @PathoPictures: It's official! papillary encapsulated thyroid neoplasm is not malignant #NIFT #NIFTP https://t.co/LTbqv91nKn
RT @Tom_J_Giordano: My first #NIFTP thyroid tumor - consult case from Lansing. https://t.co/wDyqRxjRTv https://t.co/8p65qLVJ1u https://t.co…
See latest on the New Thyroid Tumour; NIFTP https://t.co/0TNQVCtbqw An important step with major implications for patients
Classification issues affect medicine as well as psychiatry HT @DrFulli https://t.co/eX3urADBqO
RT @Tom_J_Giordano: My first #NIFTP thyroid tumor - consult case from Lansing. https://t.co/wDyqRxjRTv https://t.co/8p65qLVJ1u https://t.co…
Reclassification of a Variant of Thyroid Carcinoma https://t.co/IXLnGQ3dkR
RT @NatRevClinOncol: Name change for indolent form of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment? https://t.co/n…
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @GeronimoJrLapac: Reclassification of a Variant of Thyroid Carcinoma https://t.co/ouVMuoo1Ih
RT @headandneckpath: It is finally here. Celebrate saving patients from unnecessary surgery and treatment. https://t.co/z9oa4fbwA7
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
Reclassification of a Variant of Thyroid Carcinoma https://t.co/0j7125LMiD vía @JAMAOnc
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @YuriHiranuma: 被包型・濾胞型甲状腺乳頭がんが、良性甲状腺腫瘍にダウングレードされた。 論文: https://t.co/Ya4ETmjHmm https://t.co/p16gEkzytO
RT @YuriHiranuma: 被包型・濾胞型甲状腺乳頭がんが、良性甲状腺腫瘍にダウングレードされた。 論文: https://t.co/Ya4ETmjHmm https://t.co/p16gEkzytO
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @etosha0824: 甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
甲状腺癌の分類が変わったようです。 Reclassification of a Variant of Thyroid Carcinoma https://t.co/gy3XQy0N2g
RT @elizondomemo: Reclassification of a Variant of Thyroid Carcinoma https://t.co/fZaq6yP02j
Reclassification of a Variant of Thyroid Carcinoma https://t.co/fZaq6yP02j
RT @JAMAOnc: In ERBB2+ met #BreastCancer, neratinib v trastuzumab w/paclitaxel shows no diff in PFS or OS, nerat better in CNS https://t.co…
Reclassification of a Variant of Thyroid Carcinoma https://t.co/HV91WrP3Ha
RT @JAMAOnc: In ERBB2+ met #BreastCancer, neratinib v trastuzumab w/paclitaxel shows no diff in PFS or OS, nerat better in CNS https://t.co…
In ERBB2+ met #BreastCancer, neratinib v trastuzumab w/paclitaxel shows no diff in PFS or OS, nerat better in CNS https://t.co/UGoGCgYlMx
RT @NatRevClinOncol: Name change for indolent form of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment? https://t.co/n…
RT @NatRevClinOncol: Name change for indolent form of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment? https://t.co/n…
RT @NatRevClinOncol: Name change for indolent form of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment? https://t.co/n…